Schrödinger, Inc. (NASDAQ:SDGR) announced that its investigational drug SGR-1505 has received Fast Track designation from the ...

A prognostication tool for early classic Hodgkin's lymphoma outperformed a widely used risk-classification system for ...

Researchers from RWJBarnabas Health and Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, as well as Tufts Medical Center and The University ...

The model is called the Early-stage Hodgkin International Prognostication Index and predicts a patient’s two-year progression-free survival, according to a June 19 news release from RWJBarnabas ...

Known as the Early-stage Hodgkin International Prognostication Index (E-HIPI), the model estimates two-year progression-free survival (PFS) and is designed to support more personalized treatment ...

The E-HIPI model was developed using data from over 3,000 adult patients enrolled in four, pivotal international phase III clinical trials.

Known as the Early-stage Hodgkin International Prognostication Index (E-HIPI), the model estimates two-year progression-free survival (PFS) and ...

The E-HIPI model was developed using data from over 3,000 adult patients enrolled in four, pivotal international phase III clinical trials. To ensure its accuracy, it was tested and validated in two ...